Bishai David, Sachathep Karampreet, LeFevre Amnesty, Thant Hnin New Nwe, Zaw Min, Aung Tin, McFarland Willi, Montagu Dominic
Department of Population Family and Reproductive Health, Johns Hopkins Bloomberg School of Public Health, 615 N. Wolfe Street, Baltimore, MD 21205 USA.
Department of International Health, Johns Hopkins Bloomberg School of Public Health, 615 N. Wolfe Street, Baltimore, MD 21205 USA.
Cost Eff Resour Alloc. 2015 Feb 5;13:3. doi: 10.1186/s12962-015-0030-3. eCollection 2015.
This paper examines the cost-effectiveness of achieving increases in the use of oral rehydration solution and zinc supplementation in the management of acute diarrhea in children under 5 years through social franchising. The study uses cost and outcome data from an initiative by Population Services International (PSI) in 3 townships of Myanmar in 2010 to promote an ORS-Zinc product called ORASEL.
The objective of this study was to determine the incremental cost-effectiveness of a strategy to promote ORS-Z use through private sector franchising compared to standard government and private sector practices.
Costing from a societal perspective included program, provider, and household costs for the 2010 calendar year. Program costs including ORASEL program launch, distribution, and administration costs were obtained through a retrospective review of financial records and key informant interviews with staff in the central Yangon office. Household out of pocket payments for diarrheal episodes were obtained from a household survey conducted in the study area and additional estimates of household income lost due to parental care-giving time for a sick child were estimated. Incremental cost-effectiveness relative to status quo conditions was calculated per child death and DALY averted in 2010. Health effects included deaths and DALYs averted; the former modeled based on coverage estimates from a household survey that were entered into the Lives Saved Tool (LiST). Uncertainty was modeled with Monte Carlo methods.
Based on the model, the promotional strategy would translate to 2.85 (SD 0.29) deaths averted in a community population of 1 million where there would be 81,000 children under 5 expecting 48,373 cases of diarrhea. The incremental cost effectiveness of the franchised approach to improving ORASEL coverage is estimated at a median $5,955 (IQR: $3437-$7589) per death averted and $214 (IQR: $127-$287) per discounted DALY averted.
Investing in developing a network of private sector providers and keeping them stocked with ORS-Z as is done in a social franchise can be a highly cost-effective in terms of dollars per DALY averted.
本文探讨了通过社会特许经营增加5岁以下儿童急性腹泻管理中口服补液盐和锌补充剂使用量的成本效益。该研究使用了国际人口服务组织(PSI)2010年在缅甸3个镇区开展的一项倡议的成本和结果数据,该倡议旨在推广一种名为ORASEL的口服补液盐-锌产品。
本研究的目的是确定与标准政府和私营部门做法相比,通过私营部门特许经营促进口服补液盐-锌使用的战略的增量成本效益。
从社会角度进行成本核算,包括2010日历年的项目、提供者和家庭成本。项目成本包括ORASEL项目启动、分发和管理成本,通过对财务记录的回顾性审查以及对仰光中央办公室工作人员的关键信息访谈获得。腹泻发作的家庭自付费用来自在研究区域进行的家庭调查,并估计了因父母照顾患病儿童而损失的家庭收入的额外估计值。计算了相对于现状条件下2010年每避免一名儿童死亡和每避免一个伤残调整生命年(DALY)的增量成本效益。健康影响包括避免的死亡和伤残调整生命年;前者基于家庭调查的覆盖率估计值建模,并输入到挽救生命工具(LiST)中。不确定性采用蒙特卡罗方法建模。
根据该模型,在一个拥有100万人口的社区中,推广策略将避免2.85(标准差0.29)例死亡,其中有81000名5岁以下儿童,预计有48373例腹泻病例。改善ORASEL覆盖率的特许经营方法的增量成本效益估计为每避免一例死亡中位数为5955美元(四分位距:3437美元至7589美元),每避免一个贴现伤残调整生命年为214美元(四分位距:127美元至287美元)。
投资建立私营部门提供者网络并为其储备口服补液盐-锌,就像社会特许经营那样,就每避免一个伤残调整生命年的美元数而言,可能具有很高的成本效益。